1. Scrip
  2. >>ESG
  3. >>Diversity & Inclusion

How Janssen/HealthiVibe’s Program Found The Right Messages To Improve Trial Diversity

 
• By Alaric DeArment

Working with pharmacies was a key part of the Research Includes Me initiative. The experience also showed that listening to focus groups helped J&J provide the right education around clinical trial enrollment to reach and reassure minority communities. 

Clinical Research diagram
Janssen and HealthiVibe talked with Scrip about the Research Includes Me program • Source: Shutterstock

As Johnson & Johnson's Janssen Pharmaceutical Companies teamed up with the patient engagement company HealthiVibe on its Research Includes Me campaign to find ways to diversify the population of its Phase III COVID-19 vaccine trial, one of the approaches it took was to work with independent retail pharmacies on communication about clinical trials.

Citeline Award Nominee

Scrip is interviewing the companies shortlisted for the inaugural champion of diversity and inclusion in clinical research award, to highlight some of the best practices in this...

In May and June of 2020, the company convened nine patient focus groups, particularly of African Americans, Asian Americans and Latinos, to better understand those groups’ experiences. It then partnered...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diversity & Inclusion

Parexel Leaders On Trial Diversity, AI And What’s Holding Sponsors Back In India

 
• By Anju Ghangurde

Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 
• By Eleanor Malone

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 
• By Mary Jo Laffler

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

 
• By Mary Jo Laffler

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

More from ESG

Why Global Pull Incentives Matter For AMR Drugs

 
• By Lisa Takagi

The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

 
• By Mary Jo Laffler

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

 
• By Eleanor Malone

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.